We route international CAR-T patients to accredited Chinese hospitals with proven CAR-T and cellular-therapy programs — matched to each patient's disease and the approved product they need.
Within the MedTourChina partner network, CAR-T is delivered at institutions with the right expertise, facilities and international-patient support for your case.
Beijing · Shanghai · Guangzhou
Tertiary cancer hospitals with dedicated cellular-therapy and CAR-T units, managing complex relapsed/refractory blood cancers and high treatment volumes.
Match me to a center →Beijing · Shanghai
Pediatric CAR-T programs for childhood acute lymphoblastic leukemia and other blood cancers, with family-centered international care and parent accommodation.
Match me to a center →Multiple Cities
Hospitals with dedicated international departments (IHCU) providing interpreter services, insurance coordination and concierge support for overseas patients.
Match me to a center →The best center depends on your diagnosis, the CAR-T target you need (CD19 or BCMA), prior therapies and logistics. Our specialists shortlist 1–2 options and explain why.
Our hematology team reviews your records to confirm CAR-T eligibility and the appropriate product/target.
We match you to centers that have the approved product and the experience for your specific disease.
You receive a treatment plan, cost estimate and timeline, then we coordinate admission and travel.
Partner centers run active cellular-therapy programs with established CRS/ICANS management protocols.
Treatment episodes are typically a fraction of US/European pricing, with growing insurance coverage.
English-speaking coordinators, interpreters and dedicated international patient departments.